Department of Pediatrics and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Department of Pediatrics and Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA.
Best Pract Res Clin Haematol. 2019 Dec;32(4):101096. doi: 10.1016/j.beha.2019.101096. Epub 2019 Oct 18.
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subset of B-cell ALL with a spectrum of underlying genetic alterations that activate kinase or cytokine receptor signaling. Ph-like ALL occurs at all ages but is most common in adolescents and young adults and is postulated to be a factor in the inferior outcomes in this age group. Ph-like ALL confers a poor prognosis with conventional chemotherapy and the pediatric and adult oncology communities are conducting trials utilizing molecularly targeted approaches. In parallel, the role of immunotherapy is being assessed for this unique and biologically diverse ALL subgroup.
费城染色体样急性淋巴细胞白血病（Ph-like ALL）是 B 细胞 ALL 的一种高危亚型，具有一系列激活激酶或细胞因子受体信号的潜在遗传改变。Ph-like ALL 可发生于所有年龄段，但在青少年和年轻成人中最为常见，据推测这是该年龄组预后较差的一个因素。Ph-like ALL 对常规化疗的预后较差，儿科和成人肿瘤学领域正在开展利用分子靶向方法的试验。与此同时，免疫疗法在这一独特且具有多种生物学特性的 ALL 亚组中的作用也正在得到评估。
